All In Biotech

Drug Trial Radar · NCT00776919

Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne

A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of A Clindamycin / Benzoyl Peroxide Gel Versus Clindamycin Gel Versus Benzoyl Peroxide Gel Versus Vehicle Gel In Subjects With Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Nov 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,315 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,315

Actual

Start

Oct 2008

Primary completion

Sep 2009

Study completion Sep 2009

Sponsor

Lead sponsor
Stiefel, a GSK CompanyIndustry
Sponsor type
Industry
Collaborators
Rho, Inc.; Quintiles, Inc.; GlaxoSmithKline
First posted
Oct 22, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Randomized, Double-Blind, Controlled Study to evaluate the Safety and Efficacy of a clindamycin / benzoyl peroxide gel in Subjects with Acne Vulgaris

Conditions

  • Acne Vulgaris

Interventions

  • clindamycin / benzoyl peroxide gelDrug

    Once a day application to the face

  • clindamycin gelDrug

    Once a day application to the face

  • BPO gelDrug

    Once a day application to the face

  • vehicle gelDrug

    Once a day application to the face

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Improvement of at Least 2 Grades in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12Time frame: Baseline (Day 1) and Week 12
  2. Mean Change From Baseline (BL) to Week 12 in Inflammatory Lesion CountsTime frame: Baseline (Day 1) and Week 12
  3. Mean Change From Baseline to Week 12 in Non-inflammatory Lesion CountsTime frame: Baseline (Day 1) and Week 12
  4. Mean Change From Baseline to Week 12 in Total Lesion CountsTime frame: Baseline (Day 1) and Week 12

Locations

24 sites in 3 countries. Site status is shown where the registry gives one.

  • Rady Children's Hospital San Diego, Div. of Pediatric & Adolescents Dermatology

    San Diego, California

  • The Laser Institute for Dermatology

    Santa Monica, California

  • Cherry Creek Research, Inc.

    Denver, Colorado

  • Skin Care Research, Inc.

    Boca Raton, Florida

  • FXM Research

    Miami, Florida

  • University of Miami Cosmetic Medicine and Research Institute

    Miami Beach, Florida

  • Atlanta Dermatology & Vein Research Center, LLC

    Alpharetta, Georgia

  • SKINQRI

    Lincolnshire, Illinois

  • Dawes Fretzin Clinical Research Group

    Indianapolis, Indiana

  • DermResearch, PLLC

    Louisville, Kentucky

  • Somerset Skin Centre

    Troy, Michigan

  • Dermatology Associates of Rochester, PC

    Rochester, New York

  • DermResearch Center of New York

    Stony Brook, New York

  • The Skin Wellness Center, PC

    Knoxville, Tennessee

  • Arlington Center for Dermatology

    Arlington, Texas

  • Progressive Clinical Research

    San Antonio, Texas

  • Dermatology and Skin Care Center FXM Research International

    Belize City, Belize

  • Dr. Moguel's Clinic/FXM Research International

    Belize City, Belize

  • Nexus Clinical Research

    St. John's, Canada

  • Guildford Dermatology Specialist

    Surrey, British Columbia, Canada

  • Dermatrial Research

    Hamilton, Ontario, Canada

  • Lynderm Research, Inc.

    Markham, Ontario, Canada

  • North Bay Dermatology Centre

    North Bay, Ontario, Canada

  • CRDQ Centre de Recherche Dermatologique du Quebec

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.